Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of sIPV in Adults, Children, and Infants
NCT02985320Phase 2Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (12 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rates (SCRs) at 90 days, Post-immune geometric mean titer (GMT) at 90 days and 1 more. Started Oct 2016; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02985320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985320.